Navigation Links
Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
Date:12/21/2010

oniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products.  For additional information please visit http://www.poniard.com.

Forward Looking Statements

This release contains forward-looking statements describing, among other things, the Company's projected financial position and future operations, the adequacy of its cash resources, the Company's ongoing evaluation of strategic alternatives, the potential results of such evaluation process, the Company's goal of optimizing and realizing shareholder value from the picoplatin, the anticipated benefits to the Company of prepaying its secured credit facility, the Company's potential future sales of common stock under the equity financing facility, the availability of capital from time to time under the equity facility, and the proposed use of proceeds from any draw downs under such facility.  Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including the Company's anticipated future operating losses, need for future capital and ability to obtain future funding on favorable terms or at all; the risk that strategic relationships may not be established on a timely basis, on terms that are ultimately favorable to the Company, or at all; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's ability to retain key personnel; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
2. Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
3. Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program
4. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
5. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
6. Poniard Pharmaceuticals Announces $6.3 Million Financing
7. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
8. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
9. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
10. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
11. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... upcoming prestigious Minimally Invasive Surgery Symposium (MISS) will include ... to colon surgery, single-port bariatric surgery, transoral gastroplasty, and ... made today by MISS Executive Director Philip R Schauer, ... faculty. , The five-day CME conference, which will ...
... Calif., Oct. 27 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... teleconference with management to provide a general business overview, as ... Tuesday, November 3, 2009, at 5:00 p.m. Eastern Time (2:00 ... ended September 30, 2009 will be released earlier that day. ...
Cached Medicine Technology:Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego 2
(Date:4/18/2014)... a brain-related discovery that could revolutionize doctors, perception ... opens up the possibility that environmental and/or genetic ... activity that the researchers have identified as helping ... Neuroscience has just published a paper about ... of psychology and his doctoral student John Gaspar, ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... together nine research groups from seven countries, including teams ... and Israel, has recently been set up with the ... active sensing adopted widely in the animal kingdom, the ... ,whiskered, robotic rat. The whiskered robot will be able ...
... Medical Directions, Inc. (MDI),an independent digital medical education ... education program dealing with the,management of chronic pain ... live lectures by national experts., The study, ... Neurological,Disorders and Stroke (NINDS), was reported February 5, ...
... as better informed patients make ever-increasing demands and expect ... decisions that directly affect their care. In a ... Dr. J. Bohannon Mason of the Orthocarolina Hip and ... changes in society, the population and technology that are ...
... for Second Consecutive Year, STAMFORD, Conn., Feb. ... packaging and marketing process management,service, today announced it ... a,row by the readers of Consumer Goods Technology ... year, Paxonix was recognized with a,Best in Class ...
... Lumenis(R) Ltd. announced,today that it has scheduled a special ... accordance with the Israeli Companies,Law, of a proposed settlement ... against the Company in the federal court in New ... which has been,agreed to in principle by Lumenis and ...
... Financial Team, METAIRIE, La., Feb. 11 ... and dental practices,worldwide, has named Michael P. Beland ... responsible for all aspects of the Company,s,accounting, tax, ... am pleased that we have been able to ...
Cached Medicine News:Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 2Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 3Health News:Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts 2Health News:Doctor who? Are patients making clinical decisions? 2Health News:Paxonix Recognized for Exemplary Support in New Product Development and Implementation 2Health News:Lumenis(R) Seeks Shareholder Approval of Proposed Class Action Settlement 2Health News:Michael Beland Named as OrthoSynetics(TM) Corporate Controller 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: